Mean no. weeks with platelet responsec

durable platelet responsea

platelet response with stable dosee

( ) patients with overall platelet responseb

( ) patients with overall platelet responseb

Transient platelet response was defined as weekly platelet count 50 x 109 l for 4 or more times during study weeks 2 25 but without durable platelet response.

Durable platelet response was defined as weekly platelet count 50 x 109 l for 6 or more times for study weeks 18 25 in the absence of rescue therapies any time during the treatment period. b Overall platelet response is defined as achieving durable or transient platelet responses.

The main measure of effectiveness (complete response) was a reduction in platelet count of at least 50 from the start of treatment or to a count below 600 million ml.

.

A loss of response or failure to maintain a platelet response with romiplostim within the recommended dosing range should prompt a search for causative factors (see section 4.4, loss of response to romiplostim).

In both studies, efficacy was determined by an increase in the proportion of patients who achieved a durable

In the placebo group, 0 to 7 of patients were able achieve a platelet count response during the 6 months of treatment.

Laboratory Value (cells x 103 μ l)

Patients requiring rescue medicinal products were not considered for durable platelet response.

Platelet studies

Nadir Platelet Count (cells μ l)

confusion M

Metabolism and nutrition Rare hypokalaemia disorders ct

Clopidogrel also inhibits platelet aggregation induced by other agonists by blocking the

Clopidogrel also inhibits platelet aggregation induced by other agonists by blocking the amplification of platelet activation by released ADP.

Platelet inhibition was readily reversed, with a return of platelet function towards baseline ( 50 platelet aggregation) 4 hours after stopping a continuous infusion of 2.0 microgram kg min.

A significantly higher proportion of patients receiving romiplostim achieved a durable platelet response compared to patients receiving placebo in both studies.

INTEGRILIN is an inhibitor of platelet aggregation.

The effectiveness of Iscover as an anticoagulant was examined in a study (CAPRIE) of around 19,000 patients with atherothrombosis, where Iscover was compared with aspirin.

Platelet factor 4 does not inhibit lepirudin.

Eptifibatide inhibits platelet aggregation in a dose and concentration dependent manner as demonstrated by ex vivo platelet aggregation using adenosine diphosphate (ADP) and other agonists to induce platelet aggregation.

patients with 150,000 platelets per mm3 and more

patients with 150,000 platelets per mm³ and more

Antithrombotic agent (platelet aggregation inhibitor excl. heparin), ATC code

Monitoring of platelet counts is recommended in these patients.

Pharmacotherapeutic group platelet aggregation inhibitors excl. heparin, ATC Code

Patients who met all of the criteria for a CR except for recovery of platelet counts to 100 x 109 l Patients who met each of the following criteria Complete disappearance of circulating blasts An M2 bone marrow ( 5 and 25 blasts) and appearance of normal progenitor cells An M1 marrow that did not qualify for CR or CRp

nitric oxide since both medicinal products inhibit platelet function, their combination may in

Inhibition of platelet aggregation, platelet adhesion and release reaction

Co administration of heparin had no effect on the inhibition of platelet aggregation induced by clopidogrel.

In the second study, Kiovig was shown to be effective in increasing the platelet count.

Medicinal products that inhibit serotonin uptake may lead to reduced platelet function.

A loss of response or failure to maintain a platelet response with romiplostim treatment within the recommended dosing range should prompt a search for causative factors, including immunogenicity (see section 4.8) and increased bone marrow reticulin (see above).

Clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor, and the subsequent ADP mediated activation of the GPIIb IIIa complex, thereby inhibiting platelet aggregation.

Clopidogrel selectively inhibits the binding of adenosine diphosphate (ADP) to its platelet receptor, and the subsequent ADP mediated activation of the GPIIb IIIa complex, thereby inhibiting platelet aggregation.

ASA did not modify the clopidogrel mediated inhibition of ADP induced platelet aggregation, but clopidogrel potentiated the effect of ASA on collagen induced platelet aggregation.

Patient may not have a weekly response within 8 weeks after receiving any rescue medicinal products. c Number of weeks with platelet response is defined as number of weeks with platelet counts 50 x 109 l during study weeks 2 25.

Complete blood counts including platelets must be monitored regularly (see sections 4.4 and 4.8).

Complete blood counts including platelets must be monitored regularly (see sections 4.2 and 4.8).